$16.91
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
Country

US

CEO

Ms. Mojdeh Poul

IPO date

1995

Employees

4,427

ISIN

US4579852082

Key stats

Open

$16.82

Volume

548.56K

Market cap

$1.30B

Prev. close

$16.73

Impl / hst vl

-

Open interest

$0.00

$16.44

Day’s Range

$16.93

$8.70

52W Range

$20.49

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
0.85
P/B
1.35
Current ratio
3.60
Debt / Equity
1.79
ROE
-0.70%
Gross margin
55.80%
Income growth
-197.08%
FCF growth
-308.03

Analysts estimates

Consensus rating
Hold

The average rating from top 8 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$20.27
The top 11 analysts forecasts that 12-month price may increase by 19.88%, with a low of $14.14 and a high of $28.35
$14.14
Low
$20.27
Avg
$28.35
High
Current price

Earnings

Q2 ‘26 revenue
$418.76M
Q2 ‘26 net income
$4.48M
Revenue
Net income
Previous EPS
$0.54
Estimate EPS
$0.49
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply